TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
Caihua Xu, MD,
Dapeng Li, MD,
Weiming Duan, MD,
Min Tao, PhD
Affiliations
Caihua Xu, MD
Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
Dapeng Li, MD
Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
Weiming Duan, MD
Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
Min Tao, PhD
Corresponding author. Address for correspondence: Min Tao, PhD, First Affiliated Hospital of Soochow University, Department of Oncology, Pinghai Road No. 899, Suzhou 215002, People’s Republic of China.; Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
